Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Benzer Materyaller

• Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
  Yazar:: Stefano Molica, ve diğerleri
  Baskı/Yayın Bilgisi: (2021-06-01)
• A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
  Yazar:: Chaitra Ujjani, ve diğerleri
  Baskı/Yayın Bilgisi: (2018-04-01)
• P074 | Innovative mrd detection and immune profiling in relapsed cll treated with rituximab-venetoclax: insights from the “dedalus” protocol
  Yazar:: Maria D’Amato
  Baskı/Yayın Bilgisi: (2026-03-01)
• Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
  Yazar:: Sasanka Handunnetti, ve diğerleri
  Baskı/Yayın Bilgisi: (2021-05-01)
• PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
  Yazar:: A. R. Mato, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-06-01)